Vähä-Koskela M - Search Results

1

Adenoviral Delivery of Tumor Necrosis Factor-α and Interleukin-2 Enables Successful Adoptive Cell Therapy of Immunosuppressive Melanoma.

Siurala M, Havunen R, Saha D, Lumen D, Airaksinen AJ, Tähtinen S, Cervera-Carrascon V, Bramante S, Parviainen S, Vähä-Koskela M, Kanerva A, Hemminki A. Siurala M, et al. Mol Ther. 2016 Aug;24(8):1435-43. doi: 10.1038/mt.2016.137. Epub 2016 Jun 30. Mol Ther. 2016. PMID: 27357626 Free PMC article.

2

A high-throughput pharmacoviral approach identifies novel oncolytic virus sensitizers.

Diallo JS, Le Boeuf F, Lai F, Cox J, Vaha-Koskela M, Abdelbary H, MacTavish H, Waite K, Falls T, Wang J, Brown R, Blanchard JE, Brown ED, Kirn DH, Hiscott J, Atkins H, Lichty BD, Bell JC. Diallo JS, et al. Mol Ther. 2010 Jun;18(6):1123-9. doi: 10.1038/mt.2010.67. Epub 2010 Apr 13. Mol Ther. 2010. PMID: 20389287 Free PMC article.

3

Chapter eight--Oncolytic adenoviruses for cancer immunotherapy: data from mice, hamsters, and humans.

Cerullo V, Koski A, Vähä-Koskela M, Hemminki A. Cerullo V, et al. Adv Cancer Res. 2012;115:265-318. doi: 10.1016/B978-0-12-398342-8.00008-2. Adv Cancer Res. 2012. PMID: 23021247 Review.

4

Oncolytic adenoviruses: A potent form of tumor immunovirotherapy.

Cerullo V, Vähä-Koskela M, Hemminki A. Cerullo V, et al. Oncoimmunology. 2012 Sep 1;1(6):979-981. doi: 10.4161/onci.20172. Oncoimmunology. 2012. PMID: 23162778 Free PMC article.

5

MicroRNA-mediated suppression of oncolytic adenovirus replication in human liver.

Ylösmäki E, Lavilla-Alonso S, Jäämaa S, Vähä-Koskela M, af Hällström T, Hemminki A, Arola J, Mäkisalo H, Saksela K. Ylösmäki E, et al. PLoS One. 2013;8(1):e54506. doi: 10.1371/journal.pone.0054506. Epub 2013 Jan 22. PLoS One. 2013. PMID: 23349911 Free PMC article.

6

In vivo magnetic resonance imaging and spectroscopy identifies oncolytic adenovirus responders.

Hemminki O, Immonen R, Närväinen J, Kipar A, Paasonen J, Jokivarsi KT, Yli-Ollila H, Soininen P, Partanen K, Joensuu T, Parvianen S, Pesonen SK, Koski A, Vähä-Koskela M, Cerullo V, Pesonen S, Gröhn OH, Hemminki A. Hemminki O, et al. Int J Cancer. 2014 Jun 15;134(12):2878-90. doi: 10.1002/ijc.28615. Epub 2013 Dec 6. Int J Cancer. 2014. PMID: 24248808

7

CD40 ligand and tdTomato-armed vaccinia virus for induction of antitumor immune response and tumor imaging.

Parviainen S, Ahonen M, Diaconu I, Hirvinen M, Karttunen Å, Vähä-Koskela M, Hemminki A, Cerullo V. Parviainen S, et al. Gene Ther. 2014 Feb;21(2):195-204. doi: 10.1038/gt.2013.73. Epub 2013 Dec 5. Gene Ther. 2014. PMID: 24305418

8

Oncolytic adenovirus and doxorubicin-based chemotherapy results in synergistic antitumor activity against soft-tissue sarcoma.

Siurala M, Bramante S, Vassilev L, Hirvinen M, Parviainen S, Tähtinen S, Guse K, Cerullo V, Kanerva A, Kipar A, Vähä-Koskela M, Hemminki A. Siurala M, et al. Int J Cancer. 2015 Feb 15;136(4):945-54. doi: 10.1002/ijc.29048. Epub 2014 Jul 3. Int J Cancer. 2015. PMID: 24975392

9

GMCSF-armed vaccinia virus induces an antitumor immune response.

Parviainen S, Ahonen M, Diaconu I, Kipar A, Siurala M, Vähä-Koskela M, Kanerva A, Cerullo V, Hemminki A. Parviainen S, et al. Int J Cancer. 2015 Mar 1;136(5):1065-72. doi: 10.1002/ijc.29068. Epub 2014 Jul 10. Int J Cancer. 2015. PMID: 25042001

10

Anti-tumour activity of oncolytic Western Reserve vaccinia viruses in canine tumour cell lines, xenografts, and fresh tumour biopsies.

Autio K, Knuuttila A, Kipar A, Ahonen M, Parviainen S, Diaconu I, Kanerva A, Hakonen T, Vähä-Koskela M, Hemminki A. Autio K, et al. Vet Comp Oncol. 2016 Dec;14(4):395-408. doi: 10.1111/vco.12119. Epub 2014 Oct 10. Vet Comp Oncol. 2016. PMID: 25302859

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

65 results

Search Page

Filters